Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning to compounding pharmacies that make cheaper copies of Zepbound, since the branded treatment has been too costly and, up until recently, has been in shortage.
Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
The best companies will pay you to own them, sharing their profits via dividends. These high-quality stocks continuously grow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback